$BWAY

Moiseyev Gilad sold 5,000 shares of BWAY

Moiseyev Gilad (Chief Technology Officer) sold 5,000 shares of Brainsway Ltd. (BWAY) on 2026-06-15.

Original reporting
SEC EDGAR · Moiseyev Gilad
Published Jun 22, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BWAY
Neutral
medium confidence
Mentioned
$BWAY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BWAYNeutralLow
01

Why it matters

Insider open-market selling can be read as mild negative sentiment, but the filing lacks key details (sale price, value, and 10b5-1 plan) that would strengthen a trading thesis.

02

Market read

Traders may note the insider sale for sentiment, but the disclosure alone is unlikely to change fundamentals or drive a large repricing.

03

What to watch

Without the sale price, option/RSU context, or whether other insiders are selling/buying, the market may overinterpret the signal.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update on 2026-06-22 for a 2026-06-15 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Brainsway Ltd. (BWAY).

Company-level read

Ticker impact

$BWAYNeutralMedium confidence
Context

SEC Form 4 shows CTO Moiseyev Gilad sold 5,000 shares of Brainsway (BWAY) on 2026-06-15 under an open-market sale code.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 is primary-source, but the transaction size is modest and lacks price/plan context, so it rarely drives sustained repricing by itself.

Market effects

No sector read-across; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

The sale may be non-informational (tax/portfolio rebalancing) since the filing provides no disclosed price and states no pre-arranged 10b5-1 plan.

Key entities

  • Brainsway Ltd.

    Company whose insider transaction is disclosed via SEC Form 4.

  • Moiseyev Gilad

    Chief Technology Officer who sold 5,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BWAYMedAI 8/10

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay Ltd. (NASDAQ: BWAY) reported results from a pilot study on its Deep TMS™ technology in patients with depression and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, with measurable changes in brain activity. The study was published in the Journal of Geriatric Psychiatry and Neurology.

$BWAYMedAI 8/10

Brainsway Q2 Earnings Call Highlights

BrainsWay (NASDAQ:BWAY) reported Q2 gross profit up 34% to $12.8M with gross margin at 75%. Management cited a 30% backlog increase and SWIFT reimbursement progress, estimating 57M US covered lives. CFO Ido Marom said operating cash flow was $6.3M and raised 2026 revenue guidance to $68M-$70M. The company is also discussing Neurolief’s ProlivRx soft launch.

$BWAYHighAI 9/10

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

BrainsWay Ltd. (NASDAQ, TASE: BWAY) reported Q2 2026 revenue up 35% to $17.1 million. Adjusted EBITDA more than doubled to $3.5 million (20% margin). Remaining performance obligations rose 30% to $80.4 million, and it shipped 125 Deep TMS systems (+42% YoY). The company raised FY2026 revenue guidance to $68-$70 million and Adjusted EBITDA to $13-$14 million.

$BWAYHigh

Brainsway Ltd. (BWAY): Financial results for Q2 2026

Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding t